Cambridge, MA, United States

NeuroPhage Pharmaceuticals

www.neurophage.com
Cambridge, MA, United States

Time filter

Source Type

News Article | November 10, 2016
Site: marketersmedia.com

— The report provides comprehensive information on the therapeutics under development for Amyloidosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Amyloidosis and features dormant and discontinued projects. Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Scope - The report provides a snapshot of the global therapeutic landscape of Amyloidosis - The report reviews pipeline therapeutics for Amyloidosis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Amyloidosis therapeutics and enlists all their major and minor projects - The report assesses Amyloidosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Amyloidosis Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Amyloidosis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Amyloidosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Amyloidosis Overview 10 Therapeutics Development 11 Pipeline Products for Amyloidosis - Overview 11 Pipeline Products for Amyloidosis - Comparative Analysis 12 Amyloidosis - Therapeutics under Development by Companies 13 Amyloidosis - Therapeutics under Investigation by Universities/Institutes 15 Amyloidosis - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Amyloidosis - Products under Development by Companies 19 Amyloidosis - Products under Investigation by Universities/Institutes 21 Amyloidosis - Companies Involved in Therapeutics Development 22 Alnylam Pharmaceuticals, Inc. 22 Arcturus Therapeutics, Inc 23 Bellus Health Inc. 24 Bsim2 25 Celgene Corporation 26 GlaxoSmithKline Plc 27 Neurimmune Holding AG 28 NeuroPhage Pharmaceuticals, Inc. 29 Onyx Pharmaceuticals, Inc. 30 Pfizer Inc. 31 Prothena Corporation Plc 32 SOM Innovation Biotech SL 33 Takeda Pharmaceutical Company Limited 34 Amyloidosis - Therapeutics Assessment 35 Assessment by Monotherapy Products 35 Assessment by Combination Products 36 Assessment by Target 37 Assessment by Mechanism of Action 39 Assessment by Route of Administration 41 Assessment by Molecule Type 43 Drug Profiles 45 ALN-ANG - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 ALN-TTRsc02 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Antisense RNAi Oligonucleotides to Inhibit Amyloid Precursor Protein for Amyloidosis - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 carfilzomib - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 CLR-01 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 eprodisate disodium - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 GSK-2315698 + GSK-2398852 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 For more information, please visit http://www.wiseguyreports.com


Papisov M.I.,Harvard University | Belov V.V.,Harvard University | Gannon K.S.,NeuroPhage Pharmaceuticals
Molecular Pharmaceutics | Year: 2013

Presently, there are no effective treatments for several diseases involving the CNS, which is protected by the blood-brain, blood-CSF, and blood-arachnoid barriers. Traversing any of these barriers is difficult, especially for macromolecular drugs and particulates. However, there is significant experimental evidence that large molecules can be delivered to the CNS through the cerebrospinal fluid (CSF). The flux of the interstitial fluid in the CNS parenchyma, as well as the macro flux of CSF in the leptomeningeal space, are believed to be generally opposite to the desirable direction of CNS-targeted drug delivery. On the other hand, the available data suggest that the layer of pia mater lining the CNS surface is not continuous, and the continuity of the leptomeningeal space (LMS) with the perivascular spaces penetrating into the parenchyma provides an unexplored avenue for drug transport deep into the brain via CSF. The published data generally do not support the view that macromolecule transport from the LMS to CNS is hindered by the interstitial and CSF fluxes. The data strongly suggest that leptomeningeal transport depends on the location and volume of the administered bolus and consists of four processes: (i) pulsation-assisted convectional transport of the solutes with CSF, (ii) active "pumping" of CSF into the periarterial spaces, (iii) solute transport from the latter to and within the parenchyma, and (iv) neuronal uptake and axonal transport. The final outcome will depend on the drug molecule behavior in each of these processes, which have not been studied systematically. The data available to date suggest that many macromolecules and nanoparticles can be delivered to CNS in biologically significant amounts (>1% of the administered dose); mechanistic investigation of macromolecule and particle behavior in CSF may result in a significantly more efficient leptomeningeal drug delivery than previously thought. © 2013 American Chemical Society.


Patent
NeuroPhage Pharmaceuticals | Date: 2015-12-10

The invention relates to compositions of purified filamentous bacteriophage, as well as methods that allow reproducible purification of high concentrations of filamentous bacteriophage.


Patent
NeuroPhage Pharmaceuticals | Date: 2012-08-03

The invention relates to compositions of purified filamentous bacteriophage, as well as methods that allow reproducible purification of high concentrations of filamentous bacteriophage.


The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof wherein that g3p amino acid sequence has been modified through amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability bind to and/or disaggregate amyloid. The invention relates furthermore to the use of these variant g3p-polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.


Patent
NeuroPhage Pharmaceuticals | Date: 2013-10-01

The invention relates to agents and to pharmaceutical compositions for reducing the formation of amyloid and/or for promoting the disaggregation of amyloid proteins. The compositions may also be used to detect amyloid.


Patent
NeuroPhage Pharmaceuticals | Date: 2015-07-13

The invention relates to agents and to pharmaceutical compositions for reducing the formation of amyloid and/or for promoting the disaggregation of amyloid proteins. The compositions may also be used to detect amyloid.


Patent
NeuroPhage Pharmaceuticals | Date: 2012-11-28

The invention relates to agents and to pharmaceutical compositions for reducing the formation of amyloid and/or for promoting the disaggregation of amyloid proteins. The compositions may also be used to detect amyloid.


News Article | January 14, 2015
Site: www.finsmes.com

NeuroPhage Pharmaceuticals, Inc., a Cambridge, Massachusetts-based biotechnology company, closed $10.0m in an extension of its Series D private equity financing. This additional funding (from new investors) brought total Series D round to $27.0m. The company intends to use the funds to advance its lead drug candidate, NPT088, into clinical studies in Alzheimer’s disease by the end of 2015 and to advance innovative compounds for other diseases of protein misfolding. Led by Jonathan Solomon, Chief Executive Officer, and Franz Hefti, President and Chief Operating Officer, NeuroPhage leverages novel and proprietary GAIM (General Amyloid Interaction Motif) technology to advance NPT088 to simultaneously target multiple types of misfolded proteins found in many diseases of aging, including Alzheimer’s and Parkinson’s diseases, as well as peripheral diseases, including the systemic amyloidoses.


News Article | March 25, 2014
Site: www.finsmes.com

Unnamed new and existing backers participated in the round. The company intends to use the funds to advance its lead candidate, NPT088, and potential next-generation compounds toward clinical trials. Led by Jonathan Solomon, President and Chief Executive Officer, NeuroPhage is developing NPT088, which has the potential to treat a wide range of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and other rare diseases. The structure of this candidate is based on the company’s GAIM (General Amyloid Interaction Motif) technology platform, which recognizes both early and aggregated forms of multiple misfolded proteins and allows simultaneous targeting of multiple types of disease-related protein deposits. Related News 06/05/2013: NeuroPhage Pharmaceuticals Raises $6.4M in Equity Funding 08/03/2012: NeuroPhage Pharmaceuticals Raises $9.0M in Series B-1 Funding 01/03/2011: NeuroPhage Pharmaceuticals Raises $12.4M in Series B Financing

Loading NeuroPhage Pharmaceuticals collaborators
Loading NeuroPhage Pharmaceuticals collaborators